Whole-blood Tissue Factor Procoagulant Activity is Elevated in Type 1 Diabetes: Effects of Hyperglycemia and Hyperinsulinemia

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2012 Mar 14

PMID 22410811

Citations 12

Authors

Anamika Singh

Guenther Boden

Carol Homko

Jay Gunawardana

A Koneti Rao

Affiliations

Soon will be listed here.

Abstract

Objective: To determine tissue factor procoagulant activity (TF-PCA) in patients with type 1 diabetes and to examine effects of hyperglycemia and hyperglycemia plus hyperinsulinemia on TF-PCA.

Research Design And Methods: We have determined circulating TF-PCA and other coagulation factors under basal (hyperglycemic) conditions, after acute correction of hyperglycemia, in response to 24 h of selective hyperglycemia, and in response to 24 h of hyperglycemia plus hyperinsulinemia in nine type 1 diabetic patients and in seven nondiabetic control subjects.

Results: As shown previously in patients with type 2 diabetes, basal TF-PCA and plasma coagulation factor VIIa (FVIIa) were higher in patients with type 1 diabetes than in nondiabetic control subjects. However, in contrast with type 2 diabetes, normalizing glucose did not decrease the elevated TF-PCA levels, and raising glucose or glucose plus insulin levels did not increase TF-PCA.

Conclusions: Patients with type 1 diabetes have elevated circulating TF-PCA and FVIIa levels and are in a procoagulant state that may predispose them to acute cardiovascular events. The mechanisms regulating TF-PCA in patients with type 1 and type 2 diabetes are different and should be further explored.

Citing Articles

Platelet-monocyte aggregates: molecular mediators of thromboinflammation.

Rolling C, Barrett T, Berger J Front Cardiovasc Med. 2023; 10:960398.

PMID: 37255704 PMC: 10225702. DOI: 10.3389/fcvm.2023.960398.

Type 1 Diabetes Mellitus in the SARS-CoV-2 Pandemic: Oxidative Stress as a Major Pathophysiological Mechanism Linked to Adverse Clinical Outcomes.

Kountouri A, Korakas E, Ikonomidis I, Raptis A, Tentolouris N, Dimitriadis G Antioxidants (Basel). 2021; 10(5).

PMID: 34065123 PMC: 8151267. DOI: 10.3390/antiox10050752.

Effects of simvastatin on tissue factor pathway of blood coagulation in STATCOPE (Simvastatin in the prevention of COPD exacerbations) trial.

Rao A, Del Carpio-Cano F, Janapati S, Zhao H, Voelker H, Lu X J Thromb Haemost. 2021; 19(7):1709-1717.

PMID: 33638931 PMC: 8238804. DOI: 10.1111/jth.15282.

Type 1 diabetes is associated with an increased risk of venous thromboembolism: A retrospective population-based cohort study.

Peng Y, Lin Y, Chen C, Tsai K, Hung Y, Chen H PLoS One. 2020; 15(1):e0226997.

PMID: 31935226 PMC: 6959573. DOI: 10.1371/journal.pone.0226997.

Coagulatory Defects in Type-1 and Type-2 Diabetes.

Sobczak A, Stewart A Int J Mol Sci. 2020; 20(24).

PMID: 31888259 PMC: 6940903. DOI: 10.3390/ijms20246345.

References

Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V . Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003; 107(7):973-7. DOI: 10.1161/01.cir.0000050621.67499.7d. View

Boden G, Vaidyula V, Homko C, Mozzoli M, Rao A . Differential effects of somatostatin on circulating tissue factor procoagulant activity and protein. Am J Physiol Endocrinol Metab. 2007; 292(5):E1333-9. DOI: 10.1152/ajpendo.00483.2006. View

Ferreira I, Mocking A, Feijge M, Gorter G, van Haeften T, Heemskerk J . Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2005; 26(2):417-22. DOI: 10.1161/01.ATV.0000199519.37089.a0. View

Asakura H, Kamikubo Y, Goto A, Shiratori Y, Yamazaki M, Jokaji H . Role of tissue factor in disseminated intravascular coagulation. Thromb Res. 1995; 80(3):217-24. DOI: 10.1016/0049-3848(95)00170-v. View

Mesters R, Mannucci P, Coppola R, Keller T, Ostermann H, Kienast J . Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood. 1996; 88(3):881-6. View

Gerrits A, Koekman C, van Haeften T, Akkerman J . Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin. Diabetes. 2010; 59(6):1487-95. PMC: 2874710. DOI: 10.2337/db09-1008. View

Carmassi F, Morale M, Puccetti R, De Negri F, Monzani F, Navalesi R . Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res. 1992; 67(6):643-54. DOI: 10.1016/0049-3848(92)90068-l. View

Taylor F, Haddad P, Hack E, Chang A, Peer G, Morrissey J . Two-stage response to endotoxin infusion into normal human subjects: Correlation of blood phagocyte luminescence with clinical and laboratory markers of the inflammatory, hemostatic response. Crit Care Med. 2001; 29(2):326-34. DOI: 10.1097/00003246-200102000-00020. View

Gerrits A, Koekman C, Yildirim C, Nieuwland R, Akkerman J . Insulin inhibits tissue factor expression in monocytes. J Thromb Haemost. 2008; 7(1):198-205. DOI: 10.1111/j.1538-7836.2008.03206.x. View

10.

Aras O, Shet A, Bach R, Hysjulien J, Slungaard A, Hebbel R . Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood. 2004; 103(12):4545-53. DOI: 10.1182/blood-2003-03-0713. View

11.

Alzahrani S, Ajjan R . Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res. 2010; 7(4):260-73. DOI: 10.1177/1479164110383723. View

12.

Clauss A . [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol. 1957; 17(4):237-46. DOI: 10.1159/000205234. View

13.

Rao A, Vaidyula V, Bagga S, Jalagadugula G, Gaughan J, Wilhite D . Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost. 2006; 96(6):738-43. View

14.

Wilcox J, Smith K, Schwartz S, Gordon D . Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989; 86(8):2839-43. PMC: 287014. DOI: 10.1073/pnas.86.8.2839. View

15.

Orchard T, Costacou T, Kretowski A, Nesto R . Type 1 diabetes and coronary artery disease. Diabetes Care. 2006; 29(11):2528-38. DOI: 10.2337/dc06-1161. View

16.

Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie B, Furie B . Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood. 2004; 104(10):3190-7. DOI: 10.1182/blood-2004-03-0935. View

17.

Vaidyula V, Rao A, Mozzoli M, Homko C, Cheung P, Boden G . Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes. 2005; 55(1):202-8. View

18.

Giesen P, Rauch U, Bohrmann B, Kling D, Roque M, Fallon J . Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A. 1999; 96(5):2311-5. PMC: 26780. DOI: 10.1073/pnas.96.5.2311. View

19.

Targher G, Chonchol M, Zoppini G, Franchini M . Hemostatic disorders in type 1 diabetes mellitus. Semin Thromb Hemost. 2011; 37(1):58-65. DOI: 10.1055/s-0030-1270072. View

20.

Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y . Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100(25):2473-6. DOI: 10.1161/01.cir.100.25.2473. View